Lung Cancer Trial, Recruiting NCT06358222 Sponsor: Shanghai Chest Hospital Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06358222
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their consent to participate before the study begins
  • People aged between 18 and 75 years
  • People whose pre-surgery assessment indicates they have non-small cell lung cancer (a common type of lung cancer) at an early to intermediate stage (Stage I to IIIB), and who have not yet received any treatment for it
  • People who are newly diagnosed and have agreed to have surgery as part of their treatment
  • People who are generally well enough to carry out normal daily activities, with little or no limitation due to their illness (as measured by a standard health scoring tool used by doctors)

Who may not be able to join:

  • People whose lung cancer is confirmed after surgery to be at a stage outside the Stage I to IIIB range
  • People who have another active cancer at the same time
  • People who have a serious or poorly controlled health condition — such as uncontrolled high blood pressure, active bleeding, or an active infectious disease such as Hepatitis B, Hepatitis C, or HIV — as determined by the trial doctor
  • People who have had a lung condition called interstitial lung disease (scarring or inflammation of the lungs), whether caused by medication, radiation treatment, or any other cause
  • People who the trial doctor believes would be unable to follow the study's requirements or whose personal circumstances make participation difficult

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 021-2220000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai Chest Hospital
Registry
ClinicalTrials.gov
Start date
15 December 2023
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Negative prediction value (NPV) of lymph node metastasis rates; Disease-free survival (DFS); ctDNA-free interval (CFI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov